Frontlight ResearchEarly access
Active, not recruitingNo phase
Safety and Efficacy of the ANTHEM™ CR Total Knee System
Key facts
- Who runs it
- Smith & Nephew Pte Ltd
- Where
- India, Italy, South Africa, and South Korea8 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 153 people enrolled
- Started
- 23 Nov 2018
- Expected to end
- 1 Aug 2034
- Type of study
- Observational
- Treatments tested
- ANTHEM™ CR Total Knee System
- Record updated
- 10 March 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Subject is a candidate for primary total knee arthroplasty due to degenerative joint disease
- Subject is willing to sign and date an EC-approved consent form
- Subject has posterior cruciate ligament and all collateral ligaments intact in the index joint
- Subject is 18 to 75 years old at time of inclusion
- Subject plans to be available through ten (10) years postoperative follow-up
- Subject agrees to follow the study protocol
- Subject has achieved skeletal maturity as deemed by enrolling investigator
Who cannot take part
- Subject would receive the ANTHEM™ CR Total Knee System on the affected knee as a revision for a previously failed (TKA) or unicondylar knee arthroplasty (UKA)
- Subject received TKA on the contralateral knee as a revision for a previously failed TKA or UKA
- Subject has an active infection or sepsis (treated or untreated) or previous intra-articular infections
- Subject has contralateral lower extremity condition causing abnormal ambulation (e.g. ankle fusion, ankle arthroplasty, previous hip fracture)
- Subject has a history of patellar fracture, patellectomy, or patello-femoral Instability
- Inadequate bone stock which would make the procedure unjustifiable including but not limited to: severe osteopenia/osteoporosis or family history of severe osteoporosis/osteopenia as deemed by the enrolling investigator
- Subject has collateral ligament insufficiency
- Subject has presence of malignant tumor, either primary or metastatic, or benign tumor on leg with the knee to be treated
- Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study, including mental illness, mental retardation, drug or alcohol abuse
- Subject has conditions that may interfere with the TKA survival or outcome (e.g. Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes mellitus [i.e. not under treatment with oral/injectable medications to control blood glucose levels], fibromyalgia, moderate to severe renal insufficiency or neuromuscular disease)
- Subject has inflammatory arthritis
- Subject possesses a contralateral or ipsilateral revision hip arthroplasty
- Subject has ipsilateral hip arthritis resulting in flexion contracture
- Subject has one or more of the following arthroplasties that are not fully healed and well-functioning, as determined by the Investigator:; Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty; Contralateral primary TKA or UKA
- Women who are pregnant, nursing, or of child-bearing potential who are not utilizing highly effective birth control measures
- Participation in the treatment period of another clinical trial within thirty (30) days of Visit 1
- Any subject that meets the definition of a Vulnerable Subject per ISO14155:2011: individual whose willingness to volunteer in a clinical investigation could be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical study will evaluate the short-term (1- and 2-year) and medium term (5-year) safety and performance of the ANTHEM™ CR Total Knee System in patients with non-inflammatory degenerative joint disease of the knee requiring total knee replacement. Clinical, radiographic, Health Economic Outcomes and safety outcomes will be evaluated.
Treatments tested
- ANTHEM™ CR Total Knee System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multicentre, Cohort Study Assessing the Safety and Efficacy of the ANTHEM™ CR Total Knee System in Patients Following a Total Knee Arthroplasty
- Record updated
- 10 March 2026